Higher percentage of CD34 + CD38− cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia

References

• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073–1090.
   PubMed Web of Science ®Google Scholar
• Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003;31:731–738.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118:6037–6042.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998;351:700–708.
   PubMed Web of Science ®Google Scholar
• Cassileth P, Harrington D, Appelbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649–1656.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997;90:2978–2986.
   PubMed Web of Science ®Google Scholar
• Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332:217–223.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012;13:207–214.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Labopin M, Blaise D, et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009;27:3987–3993.
   PubMed Web of Science ®Google Scholar
• Keating S, Suciu S, de Witte T, et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML 10 trial. Leukemia 2003;17:60–67.
   PubMed Web of Science ®Google Scholar
• Feller N, Schuurhuis GI, van der Pol MA, et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003;17:68–75.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Labopin M, Reiffers J, et al. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34 + cells from leukapheresis products autografted during the first remission. Blood 2010;116:3157–3162.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood 2010;115: 1976–1984.
   PubMed Web of Science ®Google Scholar
• Sarry JE, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous whenassayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest 2011;121:384–395.
   PubMed Web of Science ®Google Scholar
• Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086–1093.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.
   PubMed Web of Science ®Google Scholar
• Van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11:6520–6527.
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, et al. High levels of CD34 + CD38low/–CD123 + blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study. Haematologica 2011;96:1792–1798.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620–625.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia: review. J Clin Oncol 1990;8:813–819.
   PubMed Web of Science ®Google Scholar
• Voog E, Le QH, Philip I, et al. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone. Ann Hematol 2001;80:584–591.
   PubMed Web of Science ®Google Scholar
• Terstappen LWMM, Huang S, Safford M, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34 + CD38- progenitor cells. Blood 1991;77:1218–1227.
   PubMed Web of Science ®Google Scholar
• Carral A, de la Rubia J, Martin G, et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003;27:5–12.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007;25:1315–1321.
   PubMed Web of Science ®Google Scholar
• Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738–743.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008;112:568–575.
   PubMed Web of Science ®Google Scholar
• McKenzie JL, Gan OI, Doedens M, et al. Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells. Exp Hematol 2007;35:1429–1436.
   PubMed Web of Science ®Google Scholar
• Kerre TC, De Smet G, De Smedt M, et al. Both CD34 + 38+ and CD34 + 38- cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J Immunol 2001;167:3692–3698.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers:implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005;106: 4086–4092.
   PubMed Web of Science ®Google Scholar
• Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007;30:607–613.
   PubMed Web of Science ®Google Scholar
• Van Rhenen A, Moghaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34 + CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007;21:1700–1707.
   PubMed Web of Science ®Google Scholar
• McKenzie JL, Gan OI, Doedens M, et al. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol 2006;7:1225–1233.
   PubMed Web of Science ®Google Scholar
• Reichle A, Rothe G, Krause S, et al. Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia 1999;13:1227–1234.
   PubMed Web of Science ®Google Scholar
• Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34 + CD38- cells in acute myeloid leukemia. Blood 2012;119:3571–3577.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One 2013;e78897.
   Google Scholar